LOGO
LOGO

Corporate News

Collegium Pharma Up 7% As Annual Revenue Outlook Better Than Street View

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024

Shares of Collegium Pharmaceutical, Inc. (COLL) are rising more than 7% Wednesday morning after the company provided full-year revenue outlook, better than analysts' view.

Collegium expects product revenues to be in the range of $565.0 million-$580.0 million for 2023.

Analysts, on average, expect revenue of $550.58 million for the year.

COLL is at $25.46 currently. It has traded in the range of $14.04-$25.98 in the last 52 weeks.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Biotech Stocks by Subscribing to RTT Biotech Investor.
Global Economics Weekly Update - Jun 01 - Jun 05, 2026

June 05, 2026 16:18 ET
A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.

Latest Updates on COVID-19